摘要
目的:对我院3种新型抗肿瘤靶向抗体药物尼妥珠单抗(nimotuzumab)、西妥昔单抗(cetux-imab)及利妥昔单抗(rituximab)进行临床应用状况回顾性评价分析。方法:查阅本院2008年10月-2009年3月临床分别应用过上述3种药物的病例,分析其出院诊断与药品说明书适应证的相符性。结果:使用过以上3种药物的病例分别为18,95和179例,与药品说明书适应证范围的相符率分别是61.11%,33.68%和70.95%;依照国内外指南推荐用法及文献资料提供的参考适应证的相符率则分别是83.33%,96.84%和98.88%。结论:该类药物临床应用时对适应证的界定目前尚无公认的标准,按照循证医学的结论,协同传统细胞毒药物合理使用该类用药是规范肿瘤化疗的方向之一。
Objective：To retrospectively evaluate the clinical application of three novel antineoplastic antibodies： nimotuzumab, cetuximab and rituximab. Methods： The patients, who were administrated with the three drugs from Oct. 2008 to Mar. 2009, were indexed. Then, the conformities between discharge diagnosis and indications of drugs were analyzed. Results ： The number of patients taken nimotuzumab, cetuximab and rituximab was 18, 95 and 179, respectively. In patients treated with the 3 antibody drugs, the conformity rates to the indications were 61.11% , 33.68% and 70.95% , respectively ;while the rats were 83.33% , 96.84% and 98.88% , respectively, on the basis of references. Conclusion：The rational use of antineoplastic antibodies will be achieved with the standards of evidence-based medicine and combination of cytotoxie drugs,although no unified standards have been established to define the indications of these drugs.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2009年第18期1798-1802,1806,共6页
Chinese Journal of New Drugs
